

# CITATION REPORT

List of articles citing

## Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

DOI: 10.1056/nejmoa2019014

New England Journal of Medicine, 2020, 383, 2041-2052.

**Source:** <https://exaly.com/paper-pdf/75866740/citation-report.pdf>

**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
803	Remdesivir Treatment for Severe COVID-19 in Third-Trimester Pregnancy: Case Report and Management Discussion. <b>2020</b> , 7, ofaa345		21
802	Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients. <b>2020</b> , 7, ofaa446		34
801	Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. <b>2020</b> , 202, 1656-1665		72
800	Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020). <b>2020</b> , 29,		50
799	Therapeutic Options Against the New Coronavirus: Updated Clinical and Laboratory Evidences. <b>2020</b> , 7, 546		5
798	Oxymetazoline for Ptosis. <b>2020</b> , 138, 1176-1177		1
797	Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review. <b>2020</b> , 80, 1929-1946		45
796	Mild SARS-CoV-2 Infection After Gene Therapy in a Child With Wiskott-Aldrich Syndrome: A Case Report. <b>2020</b> , 11, 603428		5
795	Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation. <b>2020</b> , 37, 101873		38
794	Oxidative Stress, Proton Fluxes, and Chloroquine/Hydroxychloroquine Treatment for COVID-19. <b>2020</b> , 9,		9
793	No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials". <b>2020</b> , 14, 1673-1680		31
792	Red blood cell exchange for SARS-CoV-2: A Gemini of therapeutic opportunities. <b>2020</b> , 144, 110227		2
791	Cytokine Storm in COVID-19: "When You Come Out of the Storm, You Won't Be the Same Person Who Walked in". <b>2020</b> , 11, 2132		50
790	Assessment of Chloroquine and Hydroxychloroquine Safety Profiles: A Systematic Review and Meta-Analysis. <b>2020</b> , 11, 562777		7
789	Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 2030-2040	59.2	628
788	Hydroxychloroquine in Hospitalized Patients with COVID-19: Real-World Experience Assessing Mortality. <b>2020</b> , 40, 1072-1081		9
787	Novel corona virus (COVID-19) pandemic: current status and possible strategies for detection and treatment of the disease. <b>2020</b> , 1-24		11

786	Virtual and Antiviral Screening Revive Therapeutic Drugs for COVID-19. <b>2020</b> , 3, 1278-1292	22
785	Cardiac arrest and drug-related cardiac toxicity in the Covid-19 era. Epidemiology, pathophysiology and management. <b>2020</b> , 145, 111742	3
784	Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial. <b>2020</b> , 56, 106143	51
783	Finding the right time for anti-inflammatory therapy in COVID-19. <b>2020</b> , 101, 247-248	5
782	Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials?. <b>2020</b> , 101, 107-120	5
781	Do free radical NETWORK and oxidative stress disparities in African Americans enhance their vulnerability to SARS-CoV-2 infection and COVID-19 severity?. <b>2020</b> , 37, 101721	11
780	The immuno-oncological challenge of COVID-19.. <b>2020</b> , 1, 946-964	52
779	Bioengineered Tissue Models to Study SARS-CoV-2 Pathogenesis and Therapeutic Validation. <b>2020</b> , 6, 6540-6555	13
778	The widely promoted antimalarial drug hydroxychloroquine confers no mortality benefit in hospitalized patients with COVID-19: comment on the 'Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19'. <b>2020</b> , 41, 4389-4390	3
777	COVID-19 in Brazil: the headlines should be about science. <b>2020</b> , 396, 1803	1
776	Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. <b>2020</b> , 29, 100645	34
775	Update Alert 2: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19. <b>2020</b> , 173, W128-W129	12
774	Predictors of Mortality and Effect of Drug Therapies in Mechanically Ventilated Patients With Coronavirus Disease 2019: A Multicenter Cohort Study. <b>2020</b> , 2, e0305	2
773	Risk factors for mortality in hospitalized patients with COVID-19 at the start of the pandemic in Belgium: a retrospective cohort study. <b>2020</b> , 20, 897	23
772	Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation. <b>2020</b> , 2, e0284	25
771	Update Alert 3: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19. <b>2020</b> , 173, W156-W157	17
770	Is Machine Learning a Better Way to Identify COVID-19 Patients Who Might Benefit from Hydroxychloroquine Treatment?-The IDENTIFY Trial. <b>2020</b> , 9,	6
769	Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19. <b>2020</b> , 3, e2029058	178

768	Impact of Hydroxychloroquine on Mortality in Hospitalized Patients with COVID-19: Systematic Review and Meta-Analysis. <b>2020</b> , 8,	4
767	Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline. <b>2020</b> , 6,	0
766	COVID-19 and Systemic Lupus Erythematosus: Focus on Immune Response and Therapeutics. <b>2020</b> , 11, 589474	25
765	Emerging Therapeutic Modalities against COVID-19. <b>2020</b> , 13,	11
764	Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19?. <b>2020</b> , 40, 897-899	15
763	COVID-19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes. <b>2020</b> , 72, 1981-1989	66
762	Drug treatments for covid-19: living systematic review and network meta-analysis. <b>2020</b> , 370, m2980	331
761	COVID-19 in Nursing Homes: Calming the Perfect Storm. <b>2020</b> , 68, 2153-2162	126
760	Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study. <b>2020</b> , 15, e0237693	84
759	Potential diagnostics and therapeutic approaches in COVID-19. <b>2020</b> , 510, 488-497	25
758	Understanding COVID-19: From Origin to Potential Therapeutics. <b>2020</b> , 17,	8
757	Current Options in the Treatment of COVID-19: A Review. <b>2020</b> , 13, 1999-2010	5
756	Response to: 'Correspondence on ': hydroxychloroquine, COVID-19and the role of the rheumatologist' by Graef ' by Lo. <b>2020</b> ,	1
755	Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics. <b>2020</b> , 88, 106980	20
754	COVID-19-Lessons Learned and Questions Remaining. <b>2021</b> , 72, 2225-2240	34
753	COVID-19 multidisciplinary high dependency unit: the Milan model. <b>2020</b> , 21, 260	14
752	Immunomodulatory Therapies for COVID-19 in Solid Organ Transplant Recipients. <b>2020</b> , 7, 1-11	8
751	Thinking about COVID-19 Scenario in Brazil: The Alternation between the Useful, the Uncertain and the Futile. <b>2020</b> , 42, 519-521	1

750	Clinical care of pregnant and postpartum women with COVID-19: Living recommendations from the National COVID-19 Clinical Evidence Taskforce. <b>2020</b> , 60, 840-851	18
749	Intricate interplay between Covid-19 and cardiovascular diseases. <b>2021</b> , 31, e2188	3
748	Therapeutic modalities and novel approaches in regenerative medicine for COVID-19. <b>2020</b> , 56, 106208	15
747	Observational study of azithromycin in hospitalized patients with COVID-19. <b>2020</b> , 15, e0238681	14
746	COVID-19: In the Eye of the Cytokine Storm. <b>2020</b> , 11, 558898	57
745	Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-CoV-2. <b>2020</b> , 25,	46
744	Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. <b>2020</b> , 396, 959-967	183
743	Cell and animal models of SARS-CoV-2 pathogenesis and immunity. <b>2020</b> , 13,	26
742	SARS-CoV-2 organising pneumonia: 'Has there been a widespread failure to identify and treat this prevalent condition in COVID-19?'. <b>2020</b> , 7,	52
741	Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). <b>2020</b> , 17, e1003293	36
740	SARS-CoV-2 pharmacologic therapies and their safety/effectiveness according to level of evidence. <b>2020</b> , 38, 2405-2415	10
739	SARS-CoV-2 viral clearance during bone marrow aplasia after allogeneic hematopoietic stem cell transplantation-A case report. <b>2021</b> , 25, e13875	7
738	Autophagy Augmentation to Alleviate Immune Response Dysfunction, and Resolve Respiratory and COVID-19 Exacerbations. <b>2020</b> , 9,	20
737	Targeting the sAC-Dependent cAMP Pool to Prevent SARS-Cov-2 Infection. <b>2020</b> , 9,	6
736	[COVID-19: epidemiology and clinical facts]. <b>2020</b> , 60, 893-898	1
735	Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds. <b>2020</b> , 12,	32
734	Artificial intelligence, drug repurposing and peer review. <b>2020</b> , 38, 1127-1131	35
733	Steroids and COVID-19: We Need a Precision Approach, Not One Size Fits All. <b>2020</b> , 9, 701-705	12

732	Available Compounds With Therapeutic Potential Against COVID-19: Antimicrobial Therapies, Supportive Care, and Probable Vaccines. <b>2020</b> , 11, 582025	11
731	Azithromycin for severe COVID-19. <b>2020</b> , 396, 936-937	42
730	Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltration with nafamostat mesylate. <b>2020</b> , 26, 1319-1323	5
729	Mutagenic, Genotoxic and Immunomodulatory effects of Hydroxychloroquine and Chloroquine: a review to evaluate its potential to use as a prophylactic drug against COVID-19. <b>2020</b> , 42, 25	8
728	[COVID-19 infection-update]. <b>2020</b> , 25, 1-8	
727	[Health crisis and reflexive crisis: The medical perspective in times of epidemic]. <b>2020</b> , 41, 507-509	1
726	Intensive care and anesthetic management of patients with Brugada syndrome and COVID-19 infection. <b>2020</b> , 43, 1184-1189	4
725	Antiviral Activity of Ivermectin Against SARS-CoV-2: An Old-Fashioned Dog with a New Trick Literature Review. <b>2020</b> , 88, 36	12
724	Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 and SARS-CoV. <b>2020</b> , 94,	113
723	Nano-Biomimetic Drug Delivery Vehicles: Potential Approaches for COVID-19 Treatment. <b>2020</b> , 25,	15
722	Blockage of interleukin-1 $\beta$ with canakinumab in patients with Covid-19. <b>2020</b> , 10, 21775	33
721	Autophagy Modulation in Lymphocytes From COVID-19 Patients: New Therapeutic Target in SARS-COV-2 Infection. <b>2020</b> , 11, 569849	7
720	Causal inference methods for small non-randomized studies: Methods and an application in COVID-19. <b>2020</b> , 99, 106213	4
719	Targeting Neutrophils to Treat Acute Respiratory Distress Syndrome in Coronavirus Disease. <b>2020</b> , 11, 572009	35
718	Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. <b>2020</b> , 324, 2165-2176	206
717	The Impact of Science-Unbased Measures Against COVID-19 in Clinical Decision-Making Process. <b>2020</b> , 21, 293	1
716	Misguided Use of Hydroxychloroquine for COVID-19: The Infusion of Politics Into Science. <b>2020</b> , 324, 2161-2162	43
715	[Telemedicine follow-ups for COVID-19: Experience in a tertiary hospital]. <b>2020</b> ,	3

714	Epidemiological and Clinical Characteristics of COVID-19 in Children: A Systematic Review and Meta-Analysis. <b>2020</b> , 8, 591132	33
713	In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2. <b>2020</b> , 25,	42
712	Severe Covid-19. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 2451-2460	59.2 613
711	Mild or Moderate Covid-19. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 1757-1766	59.2 627
710	Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients in Saudi Arabia. <b>2021</b> , 102, 110-114	3
709	An overview on the use of antivirals for the treatment of patients with COVID19 disease. <b>2021</b> , 30, 45-59	1
708	Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. <b>2021</b> , 3, e19-e27	28
707	Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead. <b>2021</b> , 890, 173717	14
706	Hydroxychloroquine for Prevention of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: Challenges to Trial Conduct During the Global Pandemic. <b>2021</b> , 72, e844-e847	2
705	A Strategy to Treat COVID-19 Disease With Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Preclinical Pharmacokinetic Study. <b>2021</b> , 14, 132-136	22
704	Reply to Million et al. <b>2021</b> , 72, e440-e441	
703	Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: authors' response. <b>2021</b> , 27, 138-140	8
702	Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. <b>2021</b> , 17, 46-64	209
701	Pathogenesis-directed therapy of 2019 novel coronavirus disease. <b>2021</b> , 93, 1320-1342	22
700	QTc prolongation among hydroxychloroquine sulphate-treated COVID-19 patients: An observational study. <b>2021</b> , 75, e13767	5
699	Clinical risk factors for mortality in patients with cancer and COVID-19: a systematic review and meta-analysis of recent observational studies. <b>2021</b> , 21, 107-119	16
698	[Spanish consensus document on diagnosis, stabilisation and treatment of pediatric multisystem inflammatory syndrome related to SARS-CoV-2 (SIM-PedS)]. <b>2021</b> , 94, 116.e1-116.e11	12
697	N-Glycan Modification in Covid-19 Pathophysiology: In vitro Structural Changes with Limited Functional Effects. <b>2021</b> , 41, 335-344	9

696	Repurposing medications. <b>2021</b> , 19, 336-340	4
695	Hydroxychloroquine with or without Azithromycin in Covid-19. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 190	59.2
694	SARS-CoV-2 and the COVID-19 pandemic. <b>2021</b> , 445-467	1
693	Clinical characteristics and respiratory support of 310 COVID-19 patients, diagnosed at the emergency room: a single-center retrospective study. <b>2021</b> , 16, 1051-1060	22
692	Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. <b>2021</b> , 133, 111008	14
691	Management of Arrhythmias Associated with COVID-19. <b>2020</b> , 23, 2	27
690	[Incidence of COVID-19 in patients under chronic treatment with hydroxychloroquine]. <b>2021</b> , 156, 166-171	0
689	Antibiotic use in the COVID-19 crisis in Spain. <b>2021</b> , 27, 646-647	22
688	Hydroxychloroquine vs. Azithromycin for Hospitalized Patients with COVID-19 (HAHPS): Results of a Randomized, Active Comparator Trial. <b>2020</b> ,	15
687	Hydroxychloroquine in the prevention of COVID-19 mortality. <b>2021</b> , 3, e2-e3	18
686	Clinical features and outcomes of COVID-19 in patients with solid tumors: Turkish National Registry Data. <b>2020</b> , 148, 2407	4
685	Safety and efficacy of hydroxychloroquine in 152 outpatients with confirmed COVID-19: A pilot observational study. <b>2021</b> , 40, 41-46	14
684	COVID19- clinical presentation and therapeutic considerations. <b>2021</b> , 538, 125-131	9
683	Repurposing drugs for the management of COVID-19. <b>2021</b> , 31, 295-307	23
682	Inpatient COVID-19 outcomes in solid organ transplant recipients compared to non-solid organ transplant patients: A retrospective cohort. <b>2021</b> , 21, 2498-2508	25
681	Mitigating arrhythmia risk in Hydroxychloroquine and Azithromycin treated COVID-19 patients using arrhythmia risk management plan. <b>2021</b> , 32, 100685	4
680	Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies-need for data validation of the completed trials and to improve ongoing and future randomised trial designs. <b>2021</b> , 57, 106222	13
679	In Reply - Micro-Thrombosis, Perfusion Defects, and Worsening Oxygenation in COVID-19 Patients: A Word of Caution on the Use of Convalescent Plasma. <b>2021</b> , 96, 259-261	1



678	COVID-19 and Solid Organ Transplantation: A Review Article. <b>2021</b> , 105, 37-55	111
677	COVID-19: Clouds Over the Antimicrobial Resistance Landscape. <b>2021</b> , 52, 123-126	9
676	Evidence-Based Management of the Critically Ill Adult With SARS-CoV-2 Infection. <b>2021</b> , 36, 18-41	5
675	Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. <b>2021</b> , 53, 117-134	26
674	COVID-19 in transplant recipients: The Spanish experience. <b>2021</b> , 21, 1825-1837	62
673	SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 229-237	59.2 717
672	Has the door closed on hydroxychloroquine for SARS-COV-2?. <b>2021</b> , 27, 3-5	3
671	Patient Characteristics and Outcomes of 11 721 Patients With Coronavirus Disease 2019 (COVID-19) Hospitalized Across the United States. <b>2021</b> , 72, e558-e565	61
670	Concerns About the Special Article on Hydroxychloroquine and Azithromycin in High-Risk Outpatients With COVID-19. <b>2021</b> , 190, 491-495	5
669	Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports. <b>2021</b> , 87, 1432-1442	26
668	Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen. <b>2021</b> , 324, 242-248	12
667	Azithromycin in viral infections. <b>2021</b> , 31, e2163	36
666	Pregnancy and COVID-19: pharmacologic considerations. <b>2021</b> , 57, 195-203	23
665	Cardiovascular Pathophysiology, Epidemiology, and Treatment Considerations of Coronavirus Disease 2019 (COVID-19): A Review. <b>2021</b> , 3, 28-40	3
664	Immunopathology of Hyperinflammation in COVID-19. <b>2021</b> , 191, 4-17	143
663	Optimization of hydroxychloroquine dosing scheme based on COVID-19 patients' characteristics: a review of the literature and simulations. <b>2021</b> , 51, 127-138	4
662	Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. <b>2021</b> , 10, 34-48	37
661	Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. <b>2021</b> , 27, 19-27	144

660	Azithromycin in the treatment of COVID-19: a review. <b>2021</b> , 19, 147-163	71
659	Lines of Treatment of COVID-19 Infection. <b>2021</b> , 91-144	1
658	"Kit-covid" and the Popular Pharmacy Program in Brazil. <b>2021</b> , 37, e00348020	0
657	Hydroxychloroquine in the post-COVID-19 era: will this pandemic upset decades of clinical practice?. <b>2021</b> , 40, 1649-1657	1
656	COVID-19 in Chronic Kidney Disease: The Impact of Old and Novel Cardiovascular Risk Factors. <b>2021</b> , 50, 740-749	5
655	QTc Prolongation in COVID-19 Patients Using Chloroquine. <b>2021</b> , 21, 314-321	2
654	Chinese Medicine in Fighting against Covid-19: Role and Inspiration. <b>2021</b> , 27, 3-6	4
653	Azithromycin Plus Zinc Sulfate Rapidly and Synergistically Suppresses IB $\beta$ -Mediated In Vitro Human Airway Cell ACE2 Expression for SARS-CoV-2 Entry.	2
652	Sialylation of host proteins as targetable risk factor for COVID-19 susceptibility and spreading: A hypothesis. <b>2021</b> , 3, 192-197	0
651	A pilot trial of human amniotic fluid for the treatment of COVID-19. <b>2021</b> , 14, 32	1
650	A Novel Report on the Compassionate Use of Baricitinib in Treating a Pediatric Patient With Severe Symptoms of COVID-19 Infection. <b>2021</b> , 12, 94-98	2
649	[S2k Guideline - Recommendations for Inpatient Therapy of Patients with COVID-19]. <b>2021</b> , 75, 88-112	14
648	Japanese Rapid/Living recommendations on drug management for COVID-19. <b>2021</b> , 8, e664	6
647	Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial.	4
646	COVID-19 Outbreak in Italy: Report on the First 124 Consecutive Patients Treated at Home. <b>2021</b> , 255, 61-69	0
645	Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. <b>2021</b> , 325, 254-264	157
644	Achievements of the last biennium, projections for the coming years, and the impact of COVID-19. <b>2021</b> , 47, e20210001	
643	The Astronaut and the Jabuticaba. <b>2021</b> , 116, 1-3	

642	Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies. <b>2021</b> , 12, 593223	42
641	COVID-19: Integrating the Complexity of Systemic and Pulmonary Immunopathology to Identify Biomarkers for Different Outcomes. <b>2020</b> , 11, 599736	3
640	Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update. <b>2021</b> , 49, e219-e234	119
639	The Efficacy and Safety of Hydroxychloroquine in Patients with COVID-19: A Multicenter National Retrospective Cohort. <b>2021</b> , 10, 439-455	8
638	From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?. <b>2021</b> , 28,	11
637	Disentangling the association of hydroxychloroquine treatment with mortality in Covid-19 hospitalized patients through Hierarchical Clustering.	1
636	Coronavirus (COVID-19): A Systematic Review and Meta-analysis to Evaluate the Significance of Demographics and Comorbidities. <b>2021</b> ,	4
635	Low-dose hydroxychloroquine therapy and lower mortality in hospitalized patients with COVID-19: association does not mean causality. <b>2021</b> , 57, 106254	2
634	The interplay between emerging human coronavirus infections and autophagy. <b>2021</b> , 10, 196-205	19
633	Bedside clinical data subphenotypes of critically ill COVID-19 patients: a cohort study. <b>2021</b> , 33, 196-205	
632	Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans. <b>2021</b> , 71, 342-358	0
631	Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab. <b>2021</b> , 4, 100083	20
630	Nanomaterial-based drug delivery systems as promising carriers for patients with COVID-19.. <b>2021</b> , 11, 26463-26480	7
629	Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases. <b>2021</b> , 5, rkab014	3
628	Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence. <b>2021</b> , 49, 401-410	26
627	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. <b>2021</b> ,	28
626	Ten commonly asked questions about Covid-19 and lessons learned from Thailand. <b>2021</b> , 35, 329-344	4
625	Azithromycin, RECOVERY, and the power of large, simple trials. <b>2021</b> , 397, 559-560	2

624	SARS-CoV-2 disinfection in aqueous solution by UV222 from a krypton chlorine excilamp.	2
623	Evolution of COVID-19 management in critical care: review and perspective from a hospital in the United Kingdom. <b>2021</b> , 36, 1-14	2
622	Antimicrobial use in COVID-19 patients in the first phase of the SARS-CoV-2 pandemic: Rapid review and evidence synthesis.	2
621	Intensive care management of patients with COVID-19: a practical approach. <b>2021</b> , 11, 36	28
620	Effectiveness of Antiviral and Immunomodulatory Agents in the Treatment of COVID-19: A Systematic Review. <b>2021</b> , 16, 165-183	
619	An updated systematic review and network meta-analysis of 25 randomized trials assessing the efficacy and safety of treatments in COVID-19 disease. <b>2021</b> , 10, 1945	2
618	Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. <b>2021</b> , 2, CD013587	57
617	Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH). <b>2021</b> , 22, 1127-1141	3
616	Spanish consensus document on diagnosis, stabilisation and treatment of pediatric multisystem inflammatory syndrome related to SARS-CoV-2 (SIM-PedS). <b>2021</b> , 94, 116.e1-116.e11	3
615	Comparison of the clinical performance and usefulness of five SARS-CoV-2 antibody tests. <b>2021</b> , 16, e0246536	8
614	EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. <b>2021</b> ,	19
613	Bepidil is potent against SARS-CoV-2 in vitro. <b>2021</b> , 118,	38
612	The brazilian tragedy: Where patients living at the 'Earth's lungs' die of asphyxia, and the fallacy of herd immunity is killing people. <b>2021</b> , 32, 100757	6
611	Hydroxychloroquine in patients with novel coronavirus infection (COVID-19): a case-control study. <b>2021</b> , 61, 28-39	
610	Incidence of COVID-19 in patients under chronic treatment with hydroxychloroquine. <b>2021</b> , 156, 166-171	1
609	A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic. <b>2021</b> , 12, 631139	43
608	Adjunctive Nutraceutical Therapies for COVID-19. <b>2021</b> , 22,	16
607	QTc interval prolongation in patients with systemic lupus erythematosus treated with hydroxychloroquine. <b>2021</b> , 31, 1107-1112	3

606	The Surviving Sepsis Campaign: Research Priorities for Coronavirus Disease 2019 in Critical Illness. <b>2021</b> , 49, 598-622	16
605	Antimicrobial Resistance Patterns and Antibiotic Use during Hospital Conversion in the COVID-19 Pandemic. <b>2021</b> , 10,	9
604	Efficacy and safety of Ivermectin and Hydroxychloroquine in patients with severe COVID-19. A randomized controlled trial.	10
603	Structural insights into SARS-CoV-2 spike protein and its natural mutants found in Mexican population. <b>2021</b> , 11, 4659	13
602	Use of hydroxychloroquine and chloroquine in patients with COVID-19: a meta-analysis of randomized clinical trials. <b>2021</b> , 115, 139-150	10
601	Using Medicare Data to Assess the Proarrhythmic Risk of Non-Cardiac Treatment Drugs that Prolong the QT Interval in Older Adults: An Observational Cohort Study. <b>2021</b> , 8, 173-185	2
600	Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <b>2021</b> , 397, 605-612	117
599	Web Search Engine Misinformation Notifier Extension (SEMiNExt): A Machine Learning Based Approach during COVID-19 Pandemic. <b>2021</b> , 9,	10
598	A longitudinal study of convalescent plasma (CCP) donors and correlation of ABO group, initial neutralizing antibodies (nAb), and body mass index (BMI) with nAb and anti-nucleocapsid (NP) SARS-CoV-2 antibody kinetics: Proposals for better quality of CCP collections. <b>2021</b> , 61, 1447-1460	7
597	Low Zinc Levels at Admission Associates with Poor Clinical Outcomes in SARS-CoV-2 Infection. <b>2021</b> , 13,	39
596	Modeling of SARS-CoV-2 Treatment Effects for Informed Drug Repurposing. <b>2021</b> , 12, 625678	7
595	COVID-19 Associated Pulmonary Aspergillosis in Mechanically Ventilated Patients. <b>2021</b> ,	33
594	Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain?. <b>2021</b> , 35, 101658	2
593	Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19. <b>2021</b> , 104, 441-451	10
592	A review of potential suggested drugs for coronavirus disease (COVID-19) treatment. <b>2021</b> , 895, 173890	41
591	Repurposing Quinoline and Artemisinin Antimalarials as Therapeutics for SARS-CoV-2: Rationale and Implications. <b>2021</b> , 4, 613-623	3
590	Care for Patients With Neuromuscular Disorders in the COVID-19 Pandemic Era. <b>2021</b> , 12, 607790	5
589	No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19. <b>2021</b> , 104, 34-40	4

588	A Retrospective Analysis of the Impact of the Coronavirus Disease 2019 Pandemic on Health Care Workers in a Tertiary Hospital in Turkey. <b>2021</b> , 47, 948-954	
587	Using translational in vitro-in vivo modeling to improve drug repurposing outcomes for inhaled COVID-19 therapeutics.	
586	Effect of COVID-19 medications on corrected QT interval and induction of torsade de pointes: Results of a multicenter national survey. <b>2021</b> , 75, e14182	2
585	Torsades de pointes in SARS-CoV-2 (COVID-19) pneumonia: medicine reconciliation and careful monitoring of QTc interval may help prevent cardiac complications. <b>2021</b> , 14,	4
584	Development and validation of an LC-MS/MS method for determination of hydroxychloroquine, its two metabolites, and azithromycin in EDTA-treated human plasma. <b>2021</b> , 16, e0247356	1
583	COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients. <b>2021</b> , 16, e0248128	4
582	Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen. <b>2021</b> , 12, 646676	17
581	Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. <b>2021</b> , 397, 1063-1074	105
580	Considerations of the effects of commonly investigated drugs for COVID-19 in the cholesterol synthesis pathway. <b>2021</b> , 22, 947-952	1
579	Current evidence for COVID-19 therapies: a systematic literature review. <b>2021</b> , 30,	11
578	High rates of antibiotic prescriptions in children with COVID-19 or multisystem inflammatory syndrome: A multinational experience in 990 cases from Latin America. <b>2021</b> , 110, 1902-1910	11
577	Effects of chloroquine or hydroxychloroquine treatment on non-SARS-CoV2 viral infections: A systematic review of clinical studies. <b>2021</b> , 31, e2228	4
576	An Overview of Current Knowledge of Deadly CoVs and Their Interface with Innate Immunity. <b>2021</b> , 13,	7
575	Global COVID-19 pandemic and reporting behavior - An analysis of the Food and Drug Administration adverse events reporting system. <b>2021</b> , 30, 707-715	3
574	Kidney transplantation and COVID-19 renal and patient prognosis. <b>2021</b> , 14, i21-i29	5
573	The ability of the neonatal immune response to handle SARS-CoV-2 infection. <b>2021</b> , 5, e6-e7	7
572	Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). <b>2021</b> , 16, e0248132	20
571	Macrolides May Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Entry into Cells: A Quantitative Structure Activity Relationship Study and Experimental Validation. <b>2021</b> , 61, 2016-2025	2

570	COVID-19 therapeutics for low- and middle-income countries: a review of re-purposed candidate agents with potential for near-term use and impact.	1
569	Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19. <b>2021</b> , 25, 101549	5
568	Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. <b>2021</b> , 57,	76
567	COVID-19 and obesity: what is known about the features of pathogenesis and treatment?. <b>2021</b> , 2, 17-23	1
566	Drug discovery and development targeting the life cycle of SARS-CoV-2. <b>2021</b> , 1, 151-165	3
565	COVID-19: Antiviral agents and enzyme inhibitors/receptor blockers in development. <b>2021</b> , 246, 1533-1540	1
564	Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection. <b>2021</b> , 115, 235-242	30
563	Precision therapeutic targets for COVID-19. <b>2021</b> , 18, 66	15
562	Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT). <b>2021</b> , 27, 389-395	19
561	COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa. <b>2021</b> , 17, 24	7
560	An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?. <b>2021</b> , 12, 632677	28
559	The first 12 months of COVID-19: a timeline of immunological insights. <b>2021</b> , 21, 245-256	140
558	Reply to the Letter to Editor by Lacout and colleagues: Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis. <b>2021</b> , 36, 2468-2469	
557	COVID-19 and stroke-Understanding the relationship and adapting services. A global World Stroke Organisation perspective. <b>2021</b> , 16, 241-247	4
556	The therapeutic effect and safety of the drugs for COVID-19: A systematic review and meta-analysis. <b>2021</b> , 100, e25532	
555	Repositioned Drugs for COVID-19-the Impact on Multiple Organs. <b>2021</b> , 3, 1-18	3
554	Current and New Drugs for COVID-19 Treatment and Its Effects on the Liver. <b>2021</b> , 9, 436-446	3
553	Suppression of Human Coronavirus 229E Infection in Lung Fibroblast Cells via RNA Interference. <b>2021</b> , 3,	2

552	QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis. <b>2021</b> , 30, 694-706	13
551	Hydroxychloroquine Does Not Increase the Risk of Cardiac Arrhythmia in Common Rheumatic Diseases: A Nationwide Population-Based Cohort Study. <b>2021</b> , 12, 631869	1
550	Clinical characteristics of hospitalised patients with COVID-19 and the impact on mortality: a single-network, retrospective cohort study from Pennsylvania state. <b>2021</b> , 11, e042549	2
549	Mortality in mechanically ventilated patients with COVID-19: a systematic review. <b>2021</b> , 18, 457-471	4
548	System for administering and monitoring hydroxychloroquine prophylaxis for COVID-19 in accordance with a national advisory: preliminary experience of a tertiary care institute in India. <b>2021</b> , 19, 1331-1339	2
547	An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients. <b>2021</b> , 11, 9023	21
546	Neutralizing Antibody Therapeutics for COVID-19. <b>2021</b> , 13,	44
545	Day-90 survival in critically-ill patients with COVID-19 and hydroxychloroquine: a propensity analysis. <b>2021</b> , 9, 524	
544	The Reply. <b>2021</b> , 134, e300	
543	The Rise and Fall of Hydroxychloroquine and Chloroquine in COVID-19. <b>2021</b> , 897190021997399	1
542	COVID-19: Antiviral Tedavi.	
541	Clinical outcomes of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis of global data. <b>2021</b> , 20, 102778	17
540	COVID-19 and Disease-Modifying Anti-rheumatic Drugs. <b>2021</b> , 23, 28	7
539	No Efficacy of the Combination of Lopinavir/Ritonavir Plus Hydroxychloroquine Versus Standard of Care in Patients Hospitalized With COVID-19: A Non-Randomized Comparison. <b>2021</b> , 12, 621676	0
538	Systemic toxicity of chloroquine and hydroxychloroquine: prevalence, mechanisms, risk factors, prognostic and screening possibilities. <b>2021</b> , 41, 1189-1202	5
537	A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 [the ATOMIC2 trial.	2
536	The treatment of SARS-CoV2 with antivirals and mitigation of the cytokine storm syndrome: the role of gene expression. <b>2021</b> , 64, 400-415	
535	Publications and retracted articles of COVID-19 pharmacotherapy-related research: A systematic review. <b>2021</b> , 104, 368504211016936	2



534	Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study. <b>2021</b> , 105, 245-251	8
533	Hydroxychloroquine Increased Anxiety-Like Behaviors and Disrupted the Expression of Some Related Genes in the Mouse Brain. <b>2021</b> , 12, 633112	1
532	In-silico clinical trial using high performance computational modeling of a virtual human cardiac population to assess drug-induced arrhythmic risk.	0
531	Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy. <b>2021</b> , 60, S125-S136	5
530	Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. <b>2021</b> , 105, 598-605	10
529	Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial. <b>2021</b> , 9, E693-E702	7
528	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. <b>2021</b> , 12, 2349	83
527	The time to offer treatments for COVID-19. <b>2021</b> , 30, 505-518	9
526	COVID-19 Among Patients With Inflammatory Rheumatic Diseases. <b>2021</b> , 12, 651715	6
525	COVID-19 infection and rheumatoid arthritis: mutual outburst cytokines and remedies. <b>2021</b> , 37, 929-938	4
524	Chloroquine: Autophagy inhibitor, antimalarial, bitter taste receptor agonist in fight against COVID-19, a reality check?. <b>2021</b> , 897, 173928	8
523	The efficacy and safety of hydroxychloroquine (HCQ) in treatment of COVID19 -a systematic review and meta-analysis. <b>2021</b> , 39, 159-170	4
522	Administration of high titer convalescent anti-SARS-CoV-2 plasma: From donor selection to monitoring recipient outcomes. <b>2021</b> , 82, 255-263	3
521	Predictors of severe COVID-19 in kidney transplant recipients in the different epidemic waves: Analysis of the Spanish Registry. <b>2021</b> , 21, 2573-2582	19
520	Determinants of in-hospital mortality in COVID-19; a prospective cohort study from Pakistan. <b>2021</b> , 16, e0251754	7
519	Are countries' precautionary actions against COVID-19 effective? An assessment study of 175 countries worldwide. <b>2021</b> , 29, 391-409	2
518	Liver injury, SARS-COV-2 infection and COVID-19: What physicians should really know?. <b>2021</b> , 3, 121-130	1
517	Biomarkers Linked with Dynamic Changes of Renal Function in Asymptomatic and Mildly Symptomatic COVID-19 Patients. <b>2021</b> , 11,	1

516	The Rise and Fall of Hydroxychloroquine with the COVID-19 Pandemic: Narrative Review of Selected Data. <b>2021</b> , 8, 681-691	2
515	Hydroxychloroquine as prophylaxis when treating patients with coronavirus disease 2019 □ Perception of frontline health care workers in South India. 73, 141-146	
514	The Role of Nutrition in COVID-19 Susceptibility and Severity of Disease: A Systematic Review. <b>2021</b> , 151, 1854-1878	24
513	An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β1a and hydroxychloroquine in hospitalized patients with COVID-19. <b>2021</b> , 27, 1826-1837	27
512	Effect of Hydroxychloroquine on QTc in Patients Diagnosed with COVID-19: A Systematic Review and Meta-Analysis. <b>2021</b> , 8,	
511	Measuring the QT interval on the go. <b>2021</b> , 28, 358-359	
510	The Course of COVID-19 in Four Patients with HIV During the Pandemic. <b>2021</b> , 19, 286-291	0
509	Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase. <b>2021</b> , 77, 1513-1521	2
508	Unproven Therapy Algorithms for Early SARS-CoV-2 Infection Are Dangerous. <b>2021</b> , 134, e345	
507	How COVID-19 has fundamentally changed clinical research in global health. <b>2021</b> , 9, e711-e720	20
506	Outcome Improvement Between the First Two Waves of the Coronavirus Disease 2019 Pandemic in a Single Tertiary-Care Hospital in Belgium. <b>2021</b> , 3, e0438	8
505	Antiviral treatment selection for SARS-CoV-2 pneumonia. <b>2021</b> , 15, 985-992	1
504	One Year of Coronavirus Disease 2019 (COVID-19) in Brazil: A Political and Social Overview. <b>2021</b> , 87, 44	16
503	Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. <b>2021</b> , 11, 9927	48
502	Coronavirus Disease 2019 in Kidney Transplant Recipients: Single-Center Experience and Case-Control Study. <b>2021</b> , 53, 1187-1193	4
501	Better outcome of COVID-19 positive kidney transplant recipients during the unremitting stage with optimized anticoagulation and immunosuppression. <b>2021</b> , 35, e14297	4
500	Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein Using mRNA Display. <b>2021</b> , 7, 1001-1008	8
499	Drug Repurposing for the Treatment of COVID-19: A Knowledge Graph Approach. <b>2021</b> , 4, 2100055	3

498	Recent Antiviral Treatment and Vaccination Strategies Against SARS-CoV-2. <b>2021</b> , 238, 569-578	0
497	Association of hydroxychloroquine and cardiac arrhythmia in patients with systemic lupus erythematosus: A population-based case control study. <b>2021</b> , 16, e0251918	0
496	The 15-Months Clinical Experience of SARS-CoV-2: A Literature Review of Therapies and Adjuvants. <b>2021</b> , 10,	11
495	Predictors for inpatient mortality during the first wave of the SARS-CoV-2 pandemic: A retrospective analysis. <b>2021</b> , 16, e0251262	1
494	Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence. <b>2021</b> , 14, 601-621	29
493	Evidence and the Main Adverse Effects Regarding Drug Therapies in the War Against COVID-19. <b>2021</b> , 28, 3147-3157	
492	Clinical characteristics and outcomes of 1,331 patients with COVID-19: HM Spanish Cohort. <b>2021</b> , 34, 342-352	0
491	Treatment of COVID-19 by stage: any space left for mesenchymal stem cell therapy?. <b>2021</b> , 16, 477-494	1
490	Therapeutic Agents Against COVID-19 with Clinical Evidence. <b>2021</b> , 27, 1608-1617	1
489	Management of COVID-19: current status and future prospects. <b>2021</b> , 23, 104832	6
488	Mortality, viral clearance, and other clinical outcomes of hydroxychloroquine in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials. <b>2021</b> , 14, 1101-1112	4
487	National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. <b>2021</b> , 84, 1254-1268	42
486	Low Serum Albumin Predicts Severe Outcomes in COVID-19 Infection: A Single-Center Retrospective Case-Control Study. <b>2021</b> , 13, 258-267	4
485	Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update. <b>2021</b> , 151, 112106	3
484	Risk Factors for Mortality in COVID-19 Hospitalized Patients in Piedmont, Italy: Results from the Multicenter, Regional, CORACLE Registry. <b>2021</b> , 10,	7
483	Medication safety in a pandemic: A multicentre point prevalence study of QTc monitoring of hydroxychloroquine for COVID-19. <b>2021</b> , 46, 1308-1311	1
482	The SARS-CoV-2 protein ORF3a inhibits fusion of autophagosomes with lysosomes. <b>2021</b> , 7, 31	54
481	Safety of treatment with chloroquine and hydroxychloroquine: A ten-year systematic review and meta-analysis. <b>2021</b> , 88, 63-72	4

480	Comprehensive Cardiotoxicity Assessment of COVID-19 Treatments Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. <b>2021</b> , 183, 227-239	4
479	COVID-19 in Solid Organ Transplant Recipients: a Review of the Current Literature. <b>2021</b> , 13, 1-16	4
478	Dietary Supplements and Nutraceuticals under Investigation for COVID-19 Prevention and Treatment. <b>2021</b> , 6,	25
477	Hydroxychloroquine and mortality in COVID-19 patients: a systematic review and a meta-analysis of observational studies and randomized controlled trials. <b>2021</b> , 115, 456-466	5
476	Clinical Management of COVID-19 Patients - An Update. <b>2022</b> , 52, 4-10	7
475	Quantitative Structure Analysis of Some Molecules in Drugs Used in the Treatment of COVID-19 with Topological Indices. 1-12	7
474	Efficacy and safety of azithromycin in Covid-19 patients: A systematic review and meta-analysis of randomized clinical trials. <b>2021</b> , e2258	10
473	Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality. <b>2021</b> , 62, 1940-1948	0
472	The Role of Macrolides for the Management of Community-Acquired Pneumonia and Pneumonia by the Novel Coronavirus SARS-CoV-2 (COVID-19): A Position Paper by Four Medical Societies from Greece. <b>2021</b> , 10, 1081-1095	0
471	HIV and COVID-19: Lessons From HIV and STI Harm Reduction Strategies. <b>2021</b> , 18, 261-270	2
470	Use of convalescent plasma in COVID-19 patients with immunosuppression. <b>2021</b> , 61, 2503-2511	22
469	Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. <b>2021</b> , 397, 2253-2263	150
468	Assessing efficacy of antiviral therapy for COVID-19 patients: A case study on remdesivir with bayesian synthesis design and multistate analysis. <b>2021</b> , 120 Suppl 1, S77-S85	3
467	Unbiased Analysis of Temporal Changes in Immune Serum Markers in Acute COVID-19 Infection With Emphasis on Organ Failure, Anti-Viral Treatment, and Demographic Characteristics. <b>2021</b> , 12, 650465	10
466	Hydroxychloroquine plus standard of care compared with standard of care alone in COVID-19: a meta-analysis of randomized controlled trials. <b>2021</b> , 11, 11974	9
465	An Overview of the Epidemiologic, Diagnostic and Treatment Approaches of COVID-19: What do We Know?. <b>2021</b> , 42, 1604061	2
464	Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19-a randomised double-blinded placebo-controlled trial. <b>2021</b> ,	11
463	Insights into SARS-CoV-2 evolution, potential antivirals, and vaccines. <b>2021</b> , 558, 1-12	9

462	Review of epidemic, containment strategies, clinical management, and economic evaluation of COVID-19 pandemic. <b>2021</b> , 120 Suppl 1, S6-S18	4
461	Efficacy and Safety of Hydroxychloroquine for Hospitalized COVID-19 Patients: A Systematic Review and Meta-Analysis. <b>2021</b> , 10,	3
460	Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering. <b>2021</b> , 2021, 5556207	2
459	Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal from March to October 2020. <b>2021</b> , 10,	2
458	[SARS-CoV-2 infection: Available data on 15th April 2021]. <b>2021</b> , 38, 616-625	
457	Evidence-based approach to early outpatient treatment of SARS-CoV-2 (COVID-19) infection. <b>2021</b> , 34, 464-468	1
456	Public health relevant consequences of the COVID-19 pandemic on malaria in sub-Saharan Africa: A scoping review.	0
455	COVID-19 and cytokine storm syndrome: are there lessons from macrophage activation syndrome?. <b>2021</b> , 232, 1-12	22
454	Friends or Foes? An Update on Retinal Toxicities of Systemic Medications. <b>2021</b> , 52, 302-306	
453	Evaluation of the Risk of Clinical Deterioration among Inpatients with COVID-19. <b>2021</b> , 2021, 6689669	1
452	Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A retrospective study. <b>2021</b> , 16, e0252388	2
451	An Assessment of the Impact of Coronavirus Disease (COVID-19) Pandemic on National Antimicrobial Consumption in Jordan. <b>2021</b> , 10,	11
450	Adverse Effects Associated With the Use of Antimalarials During The COVID-19 Pandemic in a Tertiary Care Center in Mexico City. <b>2021</b> , 12, 668678	2
449	Statins in COVID-19 Therapy. <b>2021</b> , 11,	2
448	COVID-19 and Preparing for Future Ecological Crises: Hopes from Metagenomics in Facing Current and Future Viral Pandemic Challenges. <b>2021</b> , 25, 336-341	0
447	Effect of Aprotinin and Avifavir Combination Therapy for Moderate COVID-19 Patients. <b>2021</b> , 13,	3
446	The Role of Dysbiosis in Critically Ill Patients With COVID-19 and Acute Respiratory Distress Syndrome. <b>2021</b> , 8, 671714	7
445	Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis. <b>2021</b> , 27, 882-889	10

444	SARS-CoV-2 Antiviral Therapy. <b>2021</b> , e0010921	12
443	PRINCIPLE trial demonstrates scope for in-pandemic improvement in primary care antibiotic stewardship: a retrospective sentinel network cohort study. <b>2021</b> , 5,	5
442	Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 1382-1392	59.2 196
441	COVID-19 and the Challenges of Chemotherapy: The Failure Case of Hydroxychloroquine in the Clinical Treatment of SARS-CoV-2 Infection. <b>2021</b> , 2,	
440	Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. <b>2021</b> , 76, 285-295	3
439	Use of placebo in clinical trials in COVID-19 pandemic times: considerations on pros, cons, challenges and limitations. <b>2021</b> ,	1
438	Hydroxychloroquine in the treatment of coronavirus disease 2019: Rapid updated systematic review and meta-analysis. <b>2021</b> , e2276	2
437	Antiviral drugs arbidol and interferon alpha-1b contribute to reducing the severity of COVID-19 patients: a retrospective cohort study. <b>2021</b> , 18, 142	6
436	Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). <b>2021</b> , 10, 1837-1885	10
435	Analysis of COVID-19 Guideline Quality and Change of Recommendations: A Systematic Review. <b>2021</b> , 2021, 1-22	0
434	Concerning Pathophysiology and Justifying Clinical Trials. <b>2021</b> , 134, e439	0
433	QTc interval prolongation, inflammation, and mortality in patients with COVID-19. <b>2021</b> , 1	0
432	Antimalarial drugs-are they beneficial in rheumatic and viral diseases?-considerations in COVID-19 pandemic. <b>2021</b> , 1	3
431	Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial. <b>2021</b> , 10, 2291-2307	7
430	Knowledge, Attitude, and Practice Regarding COVID-19 Among Healthcare Workers in Primary Healthcare Centers in Dubai: A Cross-Sectional Survey, 2020. <b>2021</b> , 9, 617679	4
429	Mortality risk factors in a Spanish cohort of oldest-old patients hospitalized with COVID-19 in an acute geriatric unit: the OCTA-COVID study. <b>2021</b> , 12, 1169-1180	4
428	Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics. <b>2021</b> , 18, 154	4
427	Key summary of German national treatment guidance for hospitalized COVID-19 patients : Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021). <b>2021</b> , 1	6

426	A Comparison of SARS-COV-2 Neutralizing Antibody Therapies in High-Risk Patients with Mild to Moderate COVID-19 Disease at a Single Academic Hospital. <b>2021,</b>	1
425	Frequency, risk factors, and outcomes of hospital readmissions of COVID-19 patients. <b>2021, 11, 13733</b>	7
424	Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19. <b>2021,</b>	3
423	Outpatient Management of COVID-19 Disease: A Holistic Patient-Centered Proposal Based on the Greek Experience. <b>2021, 11,</b>	1
422	High mortality among kidney transplant recipients diagnosed with coronavirus disease 2019: Results from the Brazilian multicenter cohort study. <b>2021, 16, e0254822</b>	9
421	SARS-CoV-2 infection during pregnancy and pregnancy-related conditions: Concerns, challenges, management and mitigation strategies-a narrative review. <b>2021, 14, 863-875</b>	15
420	The Effect of Azithromycin Plus Zinc Sulfate on ACE2 Expression through IB of Human Respiratory Cells in SARS-CoV-2: In Vitro Study. <b>2021, 1, 263-275</b>	0
419	Adverse Cardiovascular Effects of Anti-COVID-19 Drugs. <b>2021, 12, 699949</b>	7
418	Compounders of the COVID crisis: the "perfect storm".. <b>2022, 35, 133-136</b>	1
417	The evolution of Brazilian Health Sciences and the present situation. <b>2021, 3, 100044</b>	
416	Paradigm Shift in Antimicrobial Resistance Pattern of Bacterial Isolates during the COVID-19 Pandemic. <b>2021, 10,</b>	9
415	Mental health in patients with rheumatic diseases related to COVID-19 pandemic: Experience in a tertiary care center in Latin America. <b>2021, 30, 1879-1887</b>	1
414	Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance. <b>2021, 58, 106428</b>	2
413	Quantifying arrhythmic long QT effects of hydroxychloroquine and azithromycin with whole-heart optical mapping and simulations. <b>2021, 2, 394-404</b>	6
412	SARS-CoV-2 Myocarditis: Insights Into Incidence, Prognosis, and Therapeutic Implications. <b>2021, 23, 129</b>	3
411	Hospital-Level Variation in Death for Critically Ill Patients with COVID-19. <b>2021, 204,</b>	12
410	QT interval and repolarization dispersion changes during the administration of hydroxychloroquine/chloroquine with/without azithromycin in early COVID 19 pandemic: A prospective observational study from two academic hospitals in Indonesia. <b>2021, 37, 1184-1195</b>	0
409	Remdesivir and Mortality in Patients with COVID-19. <b>2021,</b>	5

408	Public health-relevant consequences of the COVID-19 pandemic on malaria in sub-Saharan Africa: a scoping review. <b>2021</b> , 20, 339	11
407	Ciclesonide Inhaler Treatment for Mild-to-Moderate COVID-19: A Randomized, Open-Label, Phase 2 Trial. <b>2021</b> , 10,	6
406	Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection: A Randomized Clinical Trial. <b>2021</b> , 326, 490-498	29
405	Sars-Cov-2 Infection in Patients on Long-Term Treatment with Macrolides in Spain: A National Cross-Sectional Study. <b>2021</b> , 10,	0
404	Effect of azithromycin and hydroxychloroquine in patients hospitalized with COVID-19: Network meta-analysis of randomized controlled trials. <b>2021</b> , 93, 6737-6749	4
403	Antirheumatic drugs and COVID-19: frustrations and hopes. <b>2021</b> , 134-139	
402	QTc prolongation and mortality in SARS-2-CoV-infected patients treated with azithromycin and hydroxychloroquine. <b>2022</b> , 23, e21-e23	0
401	Therapeutic efficacy of macrolides in management of patients with mild COVID-19. <b>2021</b> , 11, 16361	5
400	Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. <b>2021</b> , 6, 317	17
399	Early Start of Oral Clarithromycin Is Associated with Better Outcome in COVID-19 of Moderate Severity: The ACHIEVE Open-Label Single-Arm Trial. <b>2021</b> , 10, 2333-2351	3
398	Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulation cOroNavirus)-Coalition IV trial. <b>2021</b> , 238, 1-11	10
397	Discovery of Antiviral Cyclic Peptides Targeting the Main Protease of SARS-CoV-2 via mRNA Display.	
396	COVID-19: potential therapeutics for pediatric patients. <b>2021</b> , 73, 1520-1538	6
395	Fighting the pandemic with collaboration at heart: Report from cardiologists in a COVID-19-dedicated Portuguese intensive care unit. <b>2021</b> , 40, 923-928	2
394	Impact of COVID-19 on Lung Allograft and Clinical Outcomes in Lung Transplant Recipients: A Case-control Study. <b>2021</b> , 105, 2072-2079	6
393	SARS-CoV-2 Treatment: Current Therapeutic Options and the Pursuit of Tailored Therapy. <b>2021</b> , 11, 7457	6
392	A metaresearch study revealed susceptibility of Covid-19 treatment research to white hat bias: first, do no harm. <b>2021</b> , 136, 55-63	6
391	SARS Cov2 outbreak management on a landing helicopter dock: An observational retrospective study. <b>2021</b> , 51, 424-428	2



390	Immune System Disequilibrium-Neutrophils, Their Extracellular Traps, and COVID-19-Induced Sepsis. <b>2021</b> , 8, 711397	2
389	Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program. <b>2021</b> , 10, 2511-2524	2
388	Non-competitive interactions between hydroxychloroquine and azithromycin: Systematic density functional, molecular dynamics, and docking calculations. <b>2021</b> , 777, 138745	2
387	Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial. <b>2021</b> , 27, 1124-1130	18
386	Epicardial fat inflammation response to COVID-19 therapies. <b>2021</b> , 29, 1427-1433	4
385	investigation of pro-arrhythmic effects of azithromycin on the human ventricle. <b>2021</b> , 27, 101043	
384	Efficacy of chloroquine and hydroxychloroquine in treating COVID-19 infection: A meta-review of systematic reviews and an updated meta-analysis. <b>2021</b> , 43, 102135	4
383	Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE). <b>2021</b> , 39, 101086	9
382	Current status of therapeutic alternatives for COVID-19: A narrative review.. <b>2021</b> , 29, 312-327	2
381	Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA). <b>2021</b>	16
380	Risk versus Benefit of Using Hydroxychloroquine to Treat Patients with COVID-19. <b>2021</b> , 2021, 5942366	2
379	Aminoquinolines as Translational Models for Drug Repurposing: Anticancer Adjuvant Properties and Toxicokinetic-Related Features. <b>2021</b> , 2021, 3569349	0
378	Protons to Patients: targeting endosomal Na /H exchangers against COVID-19 and other viral diseases. <b>2021</b> , 288, 5071-5088	0
377	Drug-induced liver injury and COVID-19: A review for clinical practice. <b>2021</b> , 13, 1143-1153	2
376	Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study. <b>2021</b> , 16, e0257376	2
375	A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients. <b>2021</b> , 12, 698008	4
374	Clinical features and laboratory findings first case of B. 1.617.2 (delta) variant concern (VOC) in Iraq. <b>2021</b> , 69, 102814	4
373	Clinical trials with antiviral drugs against COVID-19: some progress and many shattered hopes. <b>2021</b> , 23, 6364-6376	4

372	COVID-19 Therapeutics for Low- and Middle-Income Countries: A Review of Candidate Agents with Potential for Near-Term Use and Impact. <b>2021</b> , 105, 584-595	3
371	Antirheumatic Drug Intake Influence on Occurrence of COVID-19 Infection in Ambulatory Patients with Immune-Mediated Inflammatory Diseases: A Cohort Study. <b>2021</b> , 8, 1887-1895	2
370	Mortality Variations of COVID-19 from Different Hospital Settings During Different Pandemic Phases: A Multicenter Retrospective Study. <b>2021</b> , 22, 1051-1059	1
369	Estrogen Hormone Is an Essential Sex Factor Inhibiting Inflammation and Immune Response in COVID-19. <b>2021</b> ,	1
368	Willingness to Treat with Therapies of Unknown Effectiveness in Severe COVID-19: A Survey of Intensivist Physicians. <b>2021</b> ,	1
367	Response to: Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis. <b>2021</b> , 27, 1373-1374	1
366	COVID-19 in systemic lupus erythematosus: A pooled analysis and systematic review of case reports and series. <b>2021</b> , 30, 1946-1954	5
365	Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. <b>2021</b> , 9, 729559	7
364	Lack of effect on in-hospital mortality of drugs used during COVID-19 pandemic: Findings of the retrospective multicenter COVOCA study. <b>2021</b> , 16, e0256903	0
363	Efficacy of clarithromycin in patients with mild COVID-19 pneumonia not receiving oxygen administration: protocol for an exploratory, multicentre, open-label, randomised controlled trial (CAME COVID-19 study). <b>2021</b> , 11, e053325	0
362	A hitchhiker's guide through the COVID-19 galaxy. <b>2021</b> , 232, 108849	0
361	Clinical Characteristics and Outcome of COVID-19 in Turkish Hematological Malignancy Patients. <b>2021</b> ,	0
360	Bacterial Coinfections in Coronavirus Disease 2019. <b>2021</b> , 29, 930-941	26
359	Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial. <b>2021</b> , 9, 1130-1140	25
358	Hydroxychloroquine induces oxidative DNA damage and mutation in mammalian cells. <b>2021</b> , 106, 103180	1
357	Discovery and evolution of 12N-substituted aloperine derivatives as anti-SARS-CoV-2 agents through targeting late entry stage. <b>2021</b> , 115, 105196	1
356	Efficacy and Safety of Azithromycin for the Treatment of COVID-19: A Systematic Review and Meta-analysis. <b>2021</b> , 84, 299-316	5
355	Clinical trials in COVID-19 management & prevention: A meta-epidemiological study examining methodological quality. <b>2021</b> , 139, 68-79	3

354	Assessing the quality of randomization methods in randomized control trials. <b>2021</b> , 9, 100570	
353	Lungs. <b>2022</b> , 243-256	
352	Cardiovascular Disease in the COVID-19 Era: Myocardial Injury and Thrombosis. <b>2022</b> , 737-743	0
351	What outcomes should be evaluated in critically ill patients?. <b>2021</b> , 33, 312-319	0
350	Infectious disease immunotherapies [An update: Revisiting an age-old adage in times of COVID-19. <b>2021</b> , 23, 10	
349	SARS-CoV-2 Cellular Infection and Therapeutic Opportunities: Lessons Learned from Ebola Virus. <b>2021</b> , 11,	
348	Hydroxychloroquine can potentially interfere with immune function in COVID-19 patients: Mechanisms and insights. <b>2021</b> , 38, 101810	8
347	The promising drugs included in WHO's Solidarity Project: a choice based in scientific knowledge and institutional competencies. <b>2021</b> , 116, e200603	
346	High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry. <b>2021</b> , 7,	18
345	COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment Options. <b>2021</b> , 10, 93-113	9
344	The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials. <b>2021</b> , 16, e0244778	25
343	Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. <b>2021</b> , 372, n84	186
342	Reply to letter to editor by McCullough. <b>2021</b> , 53, 335-336	
341	Hydroxychloroquine and COVID-19: a Rheumatologist's Take on the Lessons Learned. <b>2021</b> , 21, 5	4
340	COVID-19: What Do Rheumatologists Need to Know?. <b>2021</b> , 23, 5	3
339	Computational analysis of macrolides as SARS-CoV-2 main protease inhibitors: a pattern recognition study based on molecular topology and validated by molecular docking. <b>2021</b> , 45, 8654-8675	1
338	Antiviral Activity of Azithromycin (A Synthetic Macrolide) for Next Step of COVID-19. <b>2021</b> , 33, 1594-1602	
337	Antimicrobial Resistance in the Context of the Sustainable Development Goals: A Brief Review. <b>2021</b> , 11, 71-82	18

336	Revised Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Guidelines on the Treatment of Patients with COVID-19. <b>2021</b> , 53, 166-219	11
335	Rationale for azithromycin in COVID-19: an overview of existing evidence. <b>2021</b> , 8,	23
334	Hydroxychloroquine in COVID-19: therapeutic promises, current status, and environmental implications. <b>2021</b> , 28, 40431-40444	13
333	Co-infection in patients with hypoxemic pneumonia due to COVID-19 in Reunion Island. <b>2021</b> , 100, e24524	5
332	Assessing the Impact of COVID-19 on Antimicrobial Stewardship Activities/Programs in the United Kingdom. <b>2021</b> , 10,	17
331	Current state of vaccine development and targeted therapies for COVID-19: impact of basic science discoveries. <b>2021</b> , 50, 107278	22
330	Therapeutic Emergency Use Authorizations (EUAs) During Pandemics: Double-Edged Swords. <b>2021</b> ,	0
329	Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo. <b>2020</b> , 94,	1
328	Progresses in clinical studies on antiviral therapies for COVID-19-Experience and lessons in design of clinical trials. <b>2020</b> , 4, 263-274	3
327	The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients. <b>2020</b> , 15, 1501-1506	18
326	A Review on the Neurological Manifestations of COVID-19 Infection: a Mechanistic View. <b>2021</b> , 58, 536-549	17
325	COVID-19 in clinical practice: A narrative synthesis. <b>2020</b> , 50, 639-647	1
324	Natural history of COVID-19 and therapeutic options. <b>2020</b> , 16, 1159-1184	41
323	Bringing evidence from press release to the clinic in the era of COVID-19. <b>2021</b> , 76, 547-549	2
322	SARS-CoV-2 infection and the antiviral innate immune response. <b>2020</b> , 12, 963-967	12
321	Hydroxychloroquine and COVID-19: Lack of Efficacy and the Social Construction of Plausibility. <b>2020</b> , 27, e573-e583	3
320	THE TIME COURSE OF THERAPEUTIC INTERVENTIONS FOR COVID-19.	2
319	Hydroxychloroquine: mechanism of action inhibiting SARS-CoV2 entry. <b>2020</b> ,	6

318	The Effect of Early Hydroxychloroquine-based Therapy in COVID-19 Patients in Ambulatory Care Settings: A Nationwide Prospective Cohort Study.	6
317	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.	7
316	An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial.	4
315	A Neanderthal OAS1 isoform Protects Against COVID-19 Susceptibility and Severity: Results from Mendelian Randomization and Case-Control Studies.	4
314	Could nutrition modulate COVID-19 susceptibility and severity of disease? A systematic review.	8
313	A placebo-controlled double blind trial of hydroxychloroquine in mild-to-moderate COVID-19.	4
312	Low dose hydroxychloroquine is associated with lower mortality in COVID-19: a meta-analysis of 26 studies and 44,521 patients.	2
311	Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease.	10
310	Correlation of Body Mass Index (BMI), initial neutralizing antibodies (nAb), ABO group and kinetics of nAb and anti-nucleocapsid (NP) SARS-CoV-2 antibodies in convalescent plasma (CCP) donors [A longitudinal study with proposals for better quality of CCP collections.	1
309	Adverse effects of remdesivir, hydroxychloroquine, and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomized trials.	3
308	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project).	2
307	Antibiotic prescriptions in children with COVID-19 and Multisystem Inflammatory Syndrome: a multinational experience in 990 cases from Latin America.	2
306	Potent anti-SARS-CoV-2 activity by gallinamide A and analogues via inhibition of cathepsin L. <b>2020</b> ,	9
305	Characteristics and outcomes of acute respiratory distress syndrome related to COVID-19 in Belgian and French intensive care units according to antiviral strategies: the COVADIS multicentre observational study. <b>2020</b> , 10, 131	24
304	Novel respiratory infectious diseases in Korea. <b>2020</b> , 37, 286-295	1
303	Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis. <b>2020</b> , 17, e1003501	78
302	Toward in vivo-relevant hERG safety assessment and mitigation strategies based on relationships between non-equilibrium blocker binding, three-dimensional channel-blocker interactions, dynamic occupancy, dynamic exposure, and cellular arrhythmia. <b>2020</b> , 15, e0234946	5
301	Comorbidity and clinical factors associated with COVID-19 critical illness and mortality at a large public hospital in New York City in the early phase of the pandemic (March-April 2020). <b>2020</b> , 15, e0242760	18

300	Structures of the SARS-CoV-2 nucleocapsid and their perspectives for drug design. <b>2020</b> , 39, e105938	74
299	Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment - United States, January-June 2020. <b>2020</b> , 69, 1210-1215 <sup>38</sup>	
298	Treatment with Zinc is Associated with Reduced In-Hospital Mortality Among COVID-19 Patients: A Multi-Center Cohort Study. <b>2020</b> ,	15
297	The Landscape of Emerging Randomized Clinical Trial Evidence for COVID-19 Disease Stages: A Systematic Review of Global Trial Registries. <b>2020</b> , 13, 4577-4587	6
296	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications. <b>2020</b> , 13, 4673-4695	20
295	Early Insights into COVID-19 in Persons Living with HIV and Cardiovascular Manifestations. <b>2020</b> , 2, 68-74	1
294	Hydroxychloroquine in COVID-19 Patients: Pros and Cons. <b>2020</b> , 11, 597985	13
293	COVID-19-Associated Hyper-Fibrinolysis: Mechanism and Implementations. <b>2020</b> , 11, 596057	7
292	Case Report: COVID-19 Recovery from Triple Infection with , HIV, and SARS-CoV-2. <b>2020</b> , 103, 1597-1599	13
291	Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study. <b>2020</b> , 103, 1635-1639	77
290	Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo. <b>2020</b> , 103, 2419-2428	46
289	Hydroxychloroquine and Coronavirus Disease 2019: A Systematic Review of a Scientific Failure. <b>2020</b> , 11,	6
288	Dynamics of COVID-19 Outcomes is Driven by Political Landscape and Socio-Economic Factors at Local Level in Brazil.	
287	Chest computed tomography in the diagnosis of COVID-19 in patients with false negative RT-PCR. <b>2021</b> , 19, eAO6363	0
286	Ethical Considerations of Hydroxychloroquine During the COVID-19 Pandemic. <b>2021</b> , 68, 7-8	
285	COVID-19: Impact on prescribing and antimicrobial resistance. <b>2021</b> , 34 Suppl 1, 63-68	1
284	Impact of Hydroxychloroquine Treatment of COVID-19 on Cardiac Conduction: The Beat Goes On. <b>2021</b> , 1, 458-464	
283	Longitudinal urinary biomarkers of immunological activation in covid-19 patients without clinically apparent kidney disease versus acute and chronic failure. <b>2021</b> , 11, 19675	1

282	Mortality risk factors of COVID-19 infection in kidney transplantation recipients: a systematic review and meta-analysis of cohorts and clinical registries. <b>2021</b> , 11, 20073	10
281	COVID-19 and Cardiac Arrhythmias. <b>2021</b> , 41, 372-378	2
280	COVID-19 Prevalence and Outcomes among Individuals with Rheumatoid Arthritis and Systemic Lupus Erythematosus Taking Hydroxychloroquine; A Retrospective Analysis. <b>2021</b> , 15, 69-76	1
279	Antibiotics for the treatment of COVID-19. <b>2021</b> , 10, CD015025	10
278	Emergence of Ethnomedical COVID-19 Treatment: A Literature Review. <b>2021</b> , 14, 4277-4289	1
277	Telemedicine follow-ups for COVID-19: Experience in a tertiary hospital. <b>2021</b> , 95, 336-344	0
276	Microbial coinfections and superinfections in critical COVID-19: a Kenyan retrospective cohort analysis. <b>2021</b> , 1, 41-46	1
275	Comparative effectiveness of pharmacological interventions on mortality and the average length of hospital stay of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. <b>2021</b> ,	0
274	Coronavirus disease 2019 in liver transplant patients: Clinical and therapeutic aspects. <b>2021</b> , 13, 1299-1315	0
273	Impact of COVID-19 pandemic on liver, liver diseases, and liver transplantation programs in intensive care units. <b>2021</b> , 13, 1215-1233	0
272	Vitamins, supplements and COVID-19: a review of currently available evidence. <b>2021</b> , 10,	4
271	Drugs and liver injury: a not to be overlooked binomial in COVID-19. <b>2021</b> , 1-14	1
270	Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil. <b>2021</b> , 61, 60	4
269	Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trial. <b>2021</b> , 41, 101169	6
268	Impact of COVID-19 infections on hemodialysis patients in the province of Blida, Algeria. <b>2020</b> , 37, 51	1
267	SARS-CoV-2 infection and some controversies concerning therapy with chloroquine and hydroxychloroquine: case report and selected literature review. <b>2020</b> , 74, 348-353	
266	Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for Covid-19 Outpatients in Saudi Arabia.	
265	COVID-19 Drug Repositioning: Present Status and Prospects. <b>2022</b> , 645-671	0

- 264 An Interactive Simulator for COVID-19 Trend Analysis. **2021**, 0
- 263 Outcomes of COVID-19 Patients Hospitalized at Acute Care Services: Real-World Experience in the New York Metropolitan Area During the Early Pandemic Before Initiation of Clinical Trials. **2021**, 29, e88-e96
- 262 Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein using mRNA Display.
- 261 COVID-19 pandemic: ten research questions Africa must answer for itself. **2020**, 54, 107-112 1
- 260 Potentials of Interferons and Hydroxychloroquine for the Prophylaxis and Early Treatment of COVID-19. **2020**, 2, 333-340 0
- 259 A Systematic Review and Network Meta-Analysis for COVID-19 Treatments.
- 258 Adverse drug reactions and drug interactions in the treatment of hospitalized patients with coronavirus disease 2019 (COVID-19). **2021**, 1, 1
- 257 Hydroxychloroquine Use in Patients With COVID-19: A Brief Perspective on Current Clinical Trials. **2020**, 20, 350-357
- 256 Fever in the returning traveller : dual infection with SARS-CoV-2 and Plasmodium falciparum malaria. **2020**, 2, 105-108
- 255 What is pneumonia?. **2021**, 17, 210087
- 254 Systematic review and meta-analysis of the safety of chloroquine and hydroxychloroquine from randomized controlled trials on malarial and non-malarial conditions. **2021**, 10, 294 0
- 253 The immunomodulatory effects of macrolide antibiotics in respiratory disease. **2021**, 71, 102095 5
- 252 Host-modifying drugs against COVID-19: some successes, but not yet the breakthrough. **2021**,
- 251 Variation in Use of Repurposed Medications Among Patients With Coronavirus Disease 2019. From The Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study: Coronavirus Disease 2019 Registry Investigator Group. **2021**, 3, e0566 0
- 250 Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L. **2021**, 4
- 249 Efficacy of chloroquine and hydroxychloroquine in treating COVID-19 infection: a meta-review of systematic reviews and an updated meta-analysis. 1
- 248 Hydroxychloroquine increased psychiatric-like behaviors and disrupted the expression of related genes in the mouse brain.
- 247 Caring for patients in a new pandemic: the necessity and challenges of observational research. **2020**, 130, 6225-6227 2



246	Evaluation of azithromycin or hydroxychloroquine plus azithromycin combination therapy on cardiac conduction and function in guinea pigs.	
245	Predictors of QT Interval Prolongation in Critically-ill Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine.	
244	Clinical Trials in COVID-19 Management & Prevention: A Meta-epidemiological Study examining methodological quality.	
243	Hydroxicloroquine for Pre-Exposure Prophylaxis for SARS-COV-2.	
242	Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a systematic review and meta-analysis of randomized controlled trials. <b>2021</b> , 11, 93-107	9
241	Quality of life and long-term outcomes after hospitalization for COVID-19: Protocol for a prospective cohort study (Coalition VII). <b>2021</b> , 33, 31-37	
240	Cardiovascular manifestations of COVID-19: An evidence-based narrative review. <b>2021</b> , 153, 7-16	4
239	A Narrative Review of Antiviral Drugs Used for COVID-19 Pharmacotherapy. <b>2021</b> , 13, 163-171	1
238	Treatment and therapeutic agents. <b>2022</b> , 121-176	
237	The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies. <b>2021</b> , 12, 704205	13
236	Off-label use of hydroxychloroquine in COVID-19: analysis of reports of suspected adverse reactions from the Italian National Network of Pharmacovigilance. <b>2021</b> ,	1
235	Favipiravir for the Treatment of Coronavirus Disease 2019; a propensity score-matched cohort study.	
234	ESCMID COVID-19 Living guidelines: drug treatment and clinical management. <b>2021</b> ,	16
233	Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review. <b>2021</b> , 22, 304	0
232	Pharmacological Treatment Options for Coronavirus Disease-19 in Renal Patients. <b>2021</b> , 2021, 4078713	1
231	Choosing clinically interpretable summary measures and robust analytic procedures for quantifying the treatment difference in comparative clinical studies. <b>2021</b> , 40, 6235-6242	1
230	Many Trials of Hydroxychloroquine for SARS-CoV-2 Were Redundant and Potentially Unethical: An Analysis of the NIH Clinical Trials Registry. <b>2021</b> ,	0
229	Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies. <b>2021</b> , 71, 39	3

228	Mutual Pan-African support paradigm to produce scientific evidence of traditional medical practices for use against COVID-19 and emerging pandemics. <b>2021</b> , 14, e01046	1
227	Prognostic factors and combined use of tocilizumab and corticosteroids in a Spanish cohort of elderly COVID-19 patients. <b>2021</b> ,	3
226	Covid-19: surging demand for some arthritis drugs. n2700	0
225	Outcomes of Patients with Severe and Critical COVID-19 Treated with Dexamethasone: a Prospective Cohort Study. <b>2021</b> , 1-29	1
224	Recent Updates in Experimental Research and Clinical Evaluation on Drugs for COVID-19 Treatment. <b>2021</b> , 12, 732403	2
223	Discovery of Diverse Natural Products as Inhibitors of SARS-CoV-2 M Protease through Virtual Screening. <b>2021</b> ,	5
222	Immunomodulation and Reduction of Thromboembolic Risk in Hospitalized COVID-19 Patients: Systematic Review and Meta-Analysis of Randomized Trials. <b>2021</b> , 10,	1
221	A Narrative Review of Existing Options for COVID-19-Specific Treatments. <b>2021</b> , 2021, 8554192	
220	Efficacy of chloroquine and hydroxychloroquine for the treatment of hospitalized COVID-19 patients: a meta-analysis. <b>2021</b> ,	2
219	Cardiovascular manifestations of COVID-19: An evidence-based narrative review. <b>2020</b> , 153,	2
218	A comparison between virus- versus patients-centred therapeutic attempts to reduce COVID-19 mortality. <b>2021</b> , 10, 2256-2263	1
217	Recent Advances on Drugs and Vaccines for COVID-19. <b>2021</b> , 58, 469580211055630	1
216	Suspect Screening of Wastewaters to Trace Anti-Covid-19 Drugs: Potential Adverse Effects on Aquatic Environment.	
215	Study of epidemiological, clinical and evolutionary characteristics of a population of patients hospitalized for COVID-19 in Morocco. <b>2021</b> , 319, 01035	
214	Mortality risk and antibiotic use for COVID-19 in hospitalized patients over 80.. <b>2022</b> , 146, 112481	2
213	In silico analytical toolset for predictive degradation and toxicity of hazardous pollutants in water sources.. <b>2021</b> , 292, 133250	2
212	Continued use of azithromycin for mild COVID-19 in India: Evidence and implications?. <b>2021</b> , 10, 4341-4344	0
211	Therapeutic Interventions Targeting Innate Immune Receptors: A Balancing Act. <b>2021</b> ,	4

210	Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association.. <b>2022</b> , CIR0000000000001052	196
209	Liver Injury in Patients Hospitalized for COVID-19: Possible Role of Therapy.. <b>2022</b> , 10,	2
208	High-cited favorable studies for COVID-19 treatments ineffective in large trials.	
207	COVID-19: les thérapeutiques. <b>2022</b> , 1, 13-13	
206	Myasthenia gravis exacerbation and myasthenic crisis associated with COVID-19: case series and literature review.. <b>2022</b> , 43, 2271	3
205	COVID-19 in Children and Adolescents: Characteristics and Specificities in Immunocompetent and Oncohematological Patients.. <b>2022</b> , 14, e2022009	1
204	Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy.. <b>2022</b> , 18, 459-472	7
203	Repurposing Covid-19 Drug : Current Issues. <b>2022</b> , 13, 9-16	
202	Pulmonary Aspects of COVID-19.. <b>2022</b> , 73, 81-93	2
201	A Portrait of SARS-CoV-2 Infection in Patients Undergoing Hematopoietic Cell Transplantation: A Systematic Review of the Literature.. <b>2022</b> , 29, 337-349	2
200	Hydroxychloroquine/Chloroquine for the Treatment of Hospitalized Patients with COVID-19: An Individual Participant Data Meta-Analysis.. <b>2022</b> ,	1
199	EVALUATION OF THE THERAPEUTIC EFFECTS OF COMBINED HYDROXYCHLOROQUINE AND AZITHROMYCINE IN PATIENTS WITH COVID-19.	0
198	Hydroxychloroquine for COVID-19: Variation in Regional Political Preferences Predicted New Prescriptions after President Trump's Endorsement.. <b>2022</b> ,	0
197	Hydroxychloroquine/Chloroquine in COVID-19 With Focus on Hospitalized Patients [A Systematic Review.	0
196	COVID GEAS: COVID-19 National Survey in Patients With Systemic Autoimmune Diseases.. <b>2021</b> , 8, 808608	1
195	Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO).. <b>2022</b> , 8,	1
194	Clinical outcomes of immunomodulatory therapies in the management of COVID-19: A tertiary-care experience from Pakistan.. <b>2022</b> , 17, e0262608	0
193	Drugs used during the COVID-19 first wave in Vitoria-Gasteiz (Spain) and their presence in the environment.. <b>2022</b> , 820, 153122	0

192	Changes in QTc interval after hydroxychloroquine therapy in patients with COVID-19 infection: a large, retrospective, multicentre cohort study.. <b>2022</b> , 12, e051579	1
191	The Concept Of Repurposing In Covid-19 Infection. <b>2022</b> , 03,	
190	Suspect screening of wastewaters to trace anti-COVID-19 drugs: Potential adverse effects on aquatic environment.. <b>2022</b> , 824, 153756	1
189	Toward finding the difference between untreated celiac disease and COVID-19 infected patients in terms of CD4, CD25 (IL-2 R $\beta$ ), FOXP3 and IL-6 expressions as genes affecting immune homeostasis.. <b>2021</b> , 21, 462	1
188	Fighting the pandemic with collaboration at heart: Report from cardiologists in a COVID-19-dedicated Portuguese intensive care unit.. <b>2021</b> , 40, 923-928	0
187	The impact of therapeutics on mortality in hospitalised patients with COVID-19: systematic review and meta-analyses informing the European Respiratory Society living guideline.. <b>2021</b> , 30,	3
186	Cardiometabolic Morbidity and Other Prognostic Factors for Mortality in Adult Hospitalized COVID-19 Patients in North Jakarta, Indonesia.. <b>2022</b> , 17, 9	0
185	Antiviral cyclic peptides targeting the main protease of SARS-CoV-2.. <b>2022</b> , 13, 3826-3836	2
184	Physiologically-based pharmacokinetic modeling of nafamostat to support dose selection for treatment of pediatric patients with COVID-19.. <b>2022</b> , 30, 24-36	0
183	Antimicrobial agents and torsades de pointes. <b>2022</b> , 231-266	
182	Brief History, Pathophysiology, Transmission of SARS-CoV-2 Virus, and Recent Advances on Transition Metal Complexes and Nanocomposites as the Potent Antiviral Agents from COVID-19 Perspectives. <b>2022</b> , 1-48	
181	SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants.. <b>2022</b> , 11,	4
180	Appendectomy vs. Non-operative Management of Simple Appendicitis: A Post-Hoc Analysis of an EAST Multicenter Study using a Hierarchical Ordinal Scale.. <b>2022</b> ,	
179	Synergistic Adverse Effects of Azithromycin and Hydroxychloroquine on Human Cardiomyocytes at a Clinically Relevant Treatment Duration.. <b>2022</b> , 15,	1
178	Trends in characteristics and outcomes among US adults hospitalised with COVID-19 throughout 2020: an observational cohort study.. <b>2022</b> , 12, e055137	1
177	Kidney Injury in COVID-19: Epidemiology, Molecular Mechanisms and Potential Therapeutic Targets.. <b>2022</b> , 23,	1
176	Hospital bed occupancy rate is an independent risk factor for COVID-19 inpatient mortality: a pandemic epicentre cohort study.. <b>2022</b> , 12, e058171	0
175	An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN- $\beta$ 1a and hydroxychloroquine in hospitalized patients with COVID-19 [Final results from the DisCoVeRy trial.	0

174	NF- $\kappa$ B Signaling and Inflammation-Drug Repurposing to Treat Inflammatory Disorders?. <b>2022</b> , 11,	0
173	Oral pigmentation as an adverse effect of chloroquine and hydroxychloroquine use: A scoping review.. <b>2022</b> , 101,	0
172	Quantitative analysis of favipiravir and hydroxychloroquine as FDA-approved drugs for treatment of COVID-19 using synchronous spectrofluorimetry. Application to pharmaceutical formulations and biological fluids.. <b>2022</b> ,	1
171	Clinical presentation and outcomes of chronic dialysis patients with COVID-19: A single center experience from Greece.. <b>2022</b> , 11, 58-72	0
170	Role of the Microbiome in the Pathogenesis of COVID-19.. <b>2022</b> , 12, 736397	0
169	Antibiotic prescribing patterns among patients admitted to an academic teaching hospital for COVID-19 during the first wave of the pandemic in Toronto: A retrospective, controlled study. <b>2022</b> , 7, 14-22	
168	Consumption Trends of Antibiotics in Brazil During the COVID-19 Pandemic.. <b>2022</b> , 13, 844818	4
167	Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19.. <b>2022</b> , 23,	0
166	The ongoing Pharmacotherapy for ministratation of Covid 19 disease: A Review. <b>2022</b> , 66-72	
165	Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: A Phase 2/3, Multicenter, Randomized, Open-label, Controlled Trial.. <b>2022</b> , AAC0204521	1
164	Efficacy and Safety of Ivermectin and Hydroxychloroquine in Patients with Severe COVID-19: A Randomized Controlled Trial.. <b>2022</b> , 14, 160-168	3
163	Involvement of political and socio-economic factors in the spatial and temporal dynamics of COVID-19 outcomes in Brazil: A population-based study.. <b>2022</b> , 100221	3
162	Efficacy of pharmacological interventions in COVID-19: A network meta-analysis.. <b>2022</b> ,	1
161	Coronavirus disease 2019 and the liver.. <b>2022</b> ,	0
160	The Arrhythmogenic Face of COVID-19: Brugada ECG Pattern in SARS-CoV-2 Infection.. <b>2022</b> , 9,	0
159	Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials.. <b>2022</b> , 12, e048502	3
158	Topological Coindices and Quantitative Structure-Property Analysis of Antiviral Drugs Investigated in the Treatment of COVID-19. <b>2022</b> , 2022, 1-15	3
157	Zinc pyrithione is a potent inhibitor of PLPro and cathepsin L enzymes with ex vivo inhibition of SARS-CoV-2 entry and replication.	0

156	High-cited favorable studies for COVID-19 treatments ineffective in large trials.. <b>2022,</b>	1
155	Trial of Early Antiviral Therapies during Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19: a summary of the protocol and analysis plan for a decentralized randomized controlled trial.. <b>2022, 23, 273</b>	
154	Hyperinflammation in COVID-19 and suicide etiopathogenesis: Hypothesis for a nefarious collision?. <b>2022, 104606</b>	0
153	Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE - Coalition V): A double-blind, multicentre, randomised, controlled trial.. <b>2022, 11, 100243</b>	0
152	Gastrointestinal and hepatic side effects of potential treatment for COVID-19 and vaccination in patients with chronic liver diseases.. <b>2021, 13, 1850-1874</b>	1
151	Real-world response of COVID-19 patients in Mexico.	
150	Changing of therapeutic trends between the 1st and 2nd wave did not reduce COVID-19 related mortality of renal transplant recipients: a national registry study.	
149	Safety and efficacy of hydroxychloroquine for treatment of non-severe COVID-19 among adults in Uganda: a randomized open label phase II clinical trial. <b>2021, 21, 1218</b>	0
148	Clinical trials during the COVID-19 pandemic: research design and lessons. <b>2021, 214-231</b>	
147	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. <b>2021,</b>	3
146	Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists.. <b>2021, 14,</b>	2
145	Factors Affecting Hospitalization and Length of Hospitalization of the Patients with Covid-19. <b>2021, 12, 320-332</b>	
144	Drug safety of frequently used drugs and substances for self-medication in COVID-19.. <b>2022, 13, 20420986221094141</b>	
143	Assessment of Awake Prone Positioning in Hospitalized Adults With COVID-19: A Nonrandomized Controlled Trial.. <b>2022,</b>	0
142	Prevalence of ECG testing and characteristics among new hydroxychloroquine and chloroquine users within a multi-center tertiary care center.. <b>2022, 1</b>	
141	Efficacy and Safety of Fixed Combination of Hydroxychloroquine with Azithromycin Versus Hydroxychloroquine and Placebo in Patients with Mild COVID-19: Randomized, double blind, Placebo controlled trial	
140	Cell transcriptomic atlas of the non-human primate <i>Macaca fascicularis</i> .. <b>2022,</b>	2
139	Can We Really Trust the Findings of the COVID-19 Research? Quality Assessment of Randomized Controlled Trials Published on COVID-19.	

138 DataSheet\_1.docx. **2020**,

137 Image\_1.tif. **2020**,

136 Data\_Sheet\_1.PDF. **2020**,

135 Table\_1.DOCX. **2020**,

134 Table\_2.DOCX. **2020**,

133 Table\_3.DOCX. **2020**,

132 Table\_4.DOCX. **2020**,

131 Table\_5.DOCX. **2020**,

130 Table\_6.DOCX. **2020**,

129 Table\_7.DOCX. **2020**,

128 Table\_8.DOCX. **2020**,

127 DataSheet\_1.pdf. **2020**,

126 DataSheet\_2.pdf. **2020**,

125 Table\_1.xlsx. **2020**,

124 Management of patients with SARS-CoV-2 infections with focus on patients with chronic lung diseases (as of 10 January 2022) : Updated statement of the Austrian Society of Pneumology (ASP).. **2022**, 134, 399

123 Tocilizumab in addition to standard of care in the management of COVID-19: a meta-analysis of RCTs.. **2022**, 93, e2022014

1

122 A narrative review of antiviral drugs used for COVID-19 pharmacotherapy. **2021**, 13, 163

2

121 Update of the recommendations of the Sociedade Portuguesa de Cuidados Intensivos and the Infection and Sepsis Group for the approach to COVID-19 in Intensive Care Medicine.. **2022**, 33, 487-536

120	The effect of outpatient antibiotic treatment of coronavirus disease 2019 on the outcomes in the emergency department: a propensity score matching study.. <b>2022</b> , 63, 53-61	
119	Pharmacological Management. <b>2022</b> , 67-96	
118	Medos, desejos e preocupaes acerca da sindemia de Covid-19 e sofrimento psico: expericias extensionistas no sul da Bahia, Brasil. 26,	
117	The Cardiovascular Manifestations of COVID-19. <b>2022</b> ,	0
116	Decrease in Visual Acuity in a 77-Year-old Woman with Age-Related Macular Degeneration after a SARS-CoV-2 Infection Treated with Hydroxychloroquine.. <b>2022</b> , 239, 527-530	0
115	Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update.. <b>2022</b> , 109022	2
114	Metabolomic Profiling of Plasma Reveals Differential Disease Severity Markers in COVID-19 Patients.. <b>2022</b> , 13, 844283	4
113	Clinical Characteristics, Risk Factors for Severity and Pharmacotherapy in Hospitalized COVID-19 Patients in the United Arab Emirates.. <b>2022</b> , 11,	0
112	Use of combined treatment of 3rd-generation cephalosporin, azithromycin and antiviral agents on moderate SARS-CoV-2 patients in South Korea: A retrospective cohort study.. <b>2022</b> , 17, e0267645	0
111	Early Corticosteroid Therapy May Increase Ventilator-Associated Lower Respiratory Tract Infection in Critically Ill Patients with COVID-19: A Multicenter Retrospective Cohort Study. <b>2022</b> , 10, 984	1
110	Antibiotics in the prophylaxis of COVID or in the treatment of mild COVID.. <b>2022</b> , 68, 553-556	
109	QSPR Modeling with Topological Indices of Some Potential Drug Candidates against COVID-19. <b>2022</b> , 2022, 1-9	6
108	Hydroxychloroquine safety in Covid-19 vs non-Covid-19 patients: analysis of differences and potential interactions.. <b>2022</b> , 1-9	0
107	Hydroxychloroquine and Mortality in SARS-Cov-2 Infection; The HOPE- Covid-19 Registry.. <b>2022</b> , 20,	
106	Clinical and Laboratory Differences Between Delta and UK Variants of SARS-CoV-2: B.1.617.2 and B.1.1.7. <b>2022</b> ,	
105	Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review. <b>2022</b> , 15, 634	1
104	Atrial fibrillation with aberrant ventricular conduction after receiving Bamlanivimab/Etesevimab: a case report. 1-3	0
103	QTc Prolongation with the Use of Hydroxychloroquine and Concomitant Arrhythmogenic Medications: A Retrospective Study Using Electronic Health Records Data.	



102	Outcomes of 2111 COVID-19 Hospitalized Patients Treated with Hydroxychloroquine/Azithromycin and Other Regimens in Marseille, France, 2020: A Monocentric Retrospective Analysis. Volume 18, 603-617	0
101	Use of pragmatic and explanatory trial designs in acute care research: lessons from COVID-19. <b>2022</b> ,	1
100	Temperature-Based Topological Indices and QSPR Analysis of COVID-19 Drugs. 1-22	
99	Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment. <b>2022</b> ,	2
98	Death and invasive mechanical ventilation risk in hospitalized COVID-19 patients treated with anti-SARS-CoV-2 monoclonal antibodies and/or antiviral agents: A systematic review and network meta-analysis protocol. <b>2022</b> , 17, e0270196	0
97	Update March 2022: management of hospitalised adults with coronavirus disease-19 (COVID-19): a European Respiratory Society living guideline. 2200803	2
96	Temporal trends in clinical characteristics and in-hospital mortality among patients with COVID-19 in Japan for waves 1, 2, and 3: A retrospective cohort study. <b>2022</b> ,	0
95	Impact of COVID-19 on Antimicrobial Resistance in Paediatric Population: a Narrative Review.	
94	Estrogen hormone is an essential sex factor inhibiting inflammation and immune response in COVID-19. <b>2022</b> , 12,	1
93	Leveraging Real-World Data in COVID-19 Response. 1-33	
92	COVID-19 Infection in Renal Transplant Recipients at Dubai Hospital: Incidence, Clinical Profile, and Outcome. 1-9	0
91	Use of Tox21 Screening Data to Evaluate the COVID-19 Drug Candidates for Their Potential Toxic Effects and Related Pathways. 13,	0
90	The Intersection between Heart Failure and Critical Care Cardiology: An International Perspective on Structure, Staffing, and Design Considerations. <b>2022</b> ,	
89	Optimizing the Design and Analysis of Future AKI Trials. ASN.2021121605	0
88	Repurposing azithromycin in combination with last-line fosfomycin, colistin and tigecycline against Multi-Drug Resistant Klebsiella pneumoniae.	
87	Hierarchical endpoint analysis using win ratio in critical care: An exploration using the balanced solutions in intensive care study (BaSICS). <b>2022</b> , 71, 154113	
86	Mild COVID- 19 Infection: Do we have any Effective Drugs? A Narrative Review. <b>2022</b> ,	
85	Coronaviruses. <b>2023</b> , 277-306	

- 84 Interactions between COVID-19 and Lung Cancer: Lessons Learned during the Pandemic. **2022**, 14, 3598 2
- 83 Characteristics, treatment and delirium incidence of older adults hospitalized with COVID-19: a multicentre retrospective cohort study. **2022**, 10, E692-E701 0
- 82 Impact of the COVID-19 pandemic on hospital antimicrobial consumption in Croatia.
- 81 COVID-19 Secondary Infections in ICU Patients and Prevention Control Measures: A Preliminary Prospective Multicenter Study. **2022**, 11, 1016
- 80 The effect of coronavirus infection on QT and QTc intervals of hospitalized patients in Qazvin, Iran.
- 79 Environmental and ecotoxicological effects of drugs used for the treatment of COVID 19. 10, 0
- 78 A disturbed balance between blood complement protective factors (FH, ApoE) and common pathway effectors (C5a, TCC) in acute COVID-19 and during convalescence. **2022**, 12, 0
- 77 Analysis of hydroxychloroquine adverse events in COVID-19 patients reported throughout Iraqi pharmacovigilance center in VigiBase—A study based on WHO database. 11, 923
- 76 Azithromycin through the Lens of the COVID-19 Treatment. **2022**, 11, 1063 1
- 75 Humoral and cellular response in convalescent COVID-19 lupus patients. **2022**, 12,
- 74 Zinc pyrithione is a potent inhibitor of PLPro and cathepsin L enzymes with ex vivo inhibition of SARS-CoV-2 entry and replication. **2022**, 37, 2158-2168 3
- 73 Polygenic autoimmune disease risk alleles impacting B cell tolerance act in concert across shared molecular networks in mouse and in humans. 13, 0
- 72 Ventricular Tachycardia or Fibrillation Storm in Coronavirus Disease. **2022**, 2022, 1-9 0
- 71 Expert consensus on the diagnosis and treatment of severe and critical coronavirus disease 2019 (COVID-19). **2022**,
- 70 Incidence of Stroke in Randomized Trials of COVID-19 Therapeutics: A Systematic Review and Meta-Analysis. 1
- 69 Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine. **2022**, 111, 109161 2
- 68 Absence of mortality differences between the 1st and 2nd covid waves in kidney transplant recipients. **2022**, 0
- 67 Immunology. **2022**, 181-223 0

66	Elucidating the pathogenicity, diagnosis, treatment, and prevention of COVID-19: Part I. <b>2022</b> , 13, 127	0
65	COVID-19 and Pulmonary Diseases. <b>2022</b> , 230-262	0
64	Identification of Suitable Drug Combinations for Treating COVID-19 Using a Novel Machine Learning Approach: The RAIN Method. <b>2022</b> , 12, 1456	0
63	Evolution of Care and Outcomes Across Surges in Hospitalized Patients with Coronavirus Disease 2019. <b>2022</b> ,	0
62	Targeting intracellular Neu1 for Coronavirus Infection Treatment.	0
61	Saving millions of lives but some resources squandered: emerging lessons from health research system pandemic achievements and challenges. <b>2022</b> , 20,	0
60	Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic.	0
59	Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2. 13,	1
58	AMMI Canada Practice Point: Treatments for adults with COVID-19 in 2021-2022. <b>2022</b> , 7, 163-169	0
57	An algorithm to predict the need for invasive mechanical ventilation in hospitalized COVID-19 patients: the experience in Sao Paulo.	0
56	Effects of COVID-19 on Arrhythmia. <b>2022</b> , 9, 292	0
55	Hydroxychloroquine, azithromycin and methylprednisolone and in hospital survival in severe COVID-19 pneumonia. 13,	0
54	Case report: Long-lasting SARS-CoV-2 infection with post-COVID-19 condition in two patients with chronic lymphocytic leukemia: The emerging therapeutic role of casirivimab/imdevimab. 12,	1
53	Use of Drugs Associated with QT Interval Prolongation at the Hospital Level during the COVID-19 Pandemic in Colombia. <b>2022</b> , 2022, 1-10	0
52	Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysis. <b>2022</b> , 17, e0273526	0
51	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19.	6
50	Care for adults with COVID -19: living guidelines from the National COVID -19 Clinical Evidence Taskforce. <b>2022</b> , 217, 368-378	1
49	Progress, pitfalls, and path forward of drug repurposing for COVID-19 treatment. <b>2022</b> , 16, 175346662211327	0

48	Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity in a randomized clinical trial.	0
47	Cellular Landscaping of COVID-19 and Gynaecological Cancers: An Infrequent Correlation. <b>2022</b> , 2022, 1-15	0
46	The failure of drug repurposing for COVID-19 as an effect of excessive hypothesis testing and weak mechanistic evidence. <b>2022</b> , 44,	0
45	Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years. 13,	1
44	A systematic review of acute and emergency care interventions for adolescents and adults with severe acute respiratory infections including COVID-19 in low- and middle-income countries. 12,	0
43	The efficacy of Zafirlukast as a SARS-CoV-2 Helicase Inhibitor in Adult Patients with moderate COVID-19 Pneumonia (Pilot Randomized Clinical Trial). <b>2022</b> ,	0
42	Life stressors significantly impact long-term outcomes and post-acute symptoms 12-months after COVID-19 hospitalization. <b>2022</b> , 443, 120487	2
41	Hydroxychloroquine for treatment of COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials. <b>2022</b> , 20,	1
40	Biologic Functions of Hydroxychloroquine in Disease: From COVID-19 to Cancer. <b>2022</b> , 14, 2551	0
39	Drug-induced liver injury in COVID-19 treatment: Incidence, mechanisms and clinical management. 13,	0
38	The Use and Safety Risk of Repurposed Drugs for COVID-19 patients: Lessons Learned Utilizing the Food and Drug Administration's Adverse Event Reporting System.	0
37	AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants. <b>2022</b> ,	0
36	Probing the neuro-psychological changes observed with the administration of COVID-19 Drugs. <b>2022</b> , 23,	1
35	A Multi-Trait Association Analysis of Brain Disorders and Platelet Traits Identifies Novel Susceptibility Loci for Major Depression, Alzheimer's and Parkinson's Disease. <b>2023</b> , 12, 245	0
34	An Improvement in the Antimicrobial Resistance Patterns of Urinary Isolates in the Out-Of-Hospital Setting following Decreased Community Use of Antibiotics during the COVID-19 Pandemic. <b>2023</b> , 12, 126	0
33	Association between acute disease severity and one-year quality of life among post-hospitalisation COVID-19 patients: Coalition VII prospective cohort study.	0
32	Pharmacologic Therapeutics for COVID-19. <b>2023</b> , 290-318	0
31	Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial.	1

30	COVID-19: Inpatient Management. <b>2023</b> , 182-232	0
29	Management of acute COVID-19 in the pediatric population and role of antimicrobial therapy. <b>2023</b> , 99-139	0
28	Heart Disease and Stroke Statistics 2023 Update: A Report From the American Heart Association.	9
27	A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection. <b>2023</b> , 18, e0274243	0
26	Antimalarials and macrolides: a review of off-label pharmacotherapies during the first wave of the SARS-CoV-2 pandemic. 59,	0
25	Hydroxychloroquine: Time for Reappraisal of Its Effect in COVID-19 Patients. <b>2023</b> , 431-439	0
24	Targeting intracellular Neu1 for coronavirus infection treatment. <b>2023</b> , 26, 106037	0
23	The development of COVID-19 treatment. 14,	2
22	Effects of hydroxychloroquine on atrial electrophysiology in in silico wild-type and PITX2+/- atrial cardiomyocytes.	0
21	Discovery, synthesis and in silico approach of pyrrolo [3,4-c]pyrroles as SARS-CoV-2 mpro inhibitors. 1-12	0
20	Dry powder formulation of azithromycin for COVID-19 therapeutics. 1-16	0
19	Current and Emerging Therapies for COVID-19 in Lung Transplantation.	0
18	The Democratic Virtues of Randomized Trials. <b>2022</b> ,	0
17	Regulating the microenvironment with nanomaterials: Potential strategies to ameliorate COVID-19. <b>2023</b> ,	0
16	The Cardiovascular Manifestations of COVID-19. <b>2023</b> , 19, 153-161	0
15	A Randomized Clinical Trial Testing Hydroxychloroquine for Reduction of SARS-CoV-2 Viral Shedding and Hospitalization in Early Outpatient COVID-19 Infection. <b>2023</b> , 11,	0
14	Risk of hospitalization and sequelae in patients with COVID-19 treated with 3-day early remdesivir vs. controls in the vaccine and Omicron era: A real-life cohort study. <b>2023</b> , 95,	0
13	The Spectrum of COVID-19-Induced Liver Injury in Various Age and Risk Groups. <b>2023</b> ,	0

- 12 Rivaroxabana em Pacientes Ambulatoriais com COVID-19 Leve ou Moderada: Fundamenta e Desenho do Estudo CARE (CARE [Coalition COVID-19 Brazil VIII]). **2023**, 120, ○
- 11 Clinical considerations with use of psychotropic medications in COVID-19 patients. **2022**, 18, 59 ○
- 10 Diagnosis, treatment protocols, and outcomes of liver transplant recipients infected with COVID-19. 11, 2140-2159 ○
- 9 Early Treatment with Hydroxychloroquine and Azithromycin: A Real-Life Monocentric Retrospective Cohort Study of 30,423 COVID-19 Patients. ○
- 8 Iniciativas Brasileiras Lideram com Forte Coopera Cientfica para Enfrentar Questes da COVID-19: O Caso da Coaliz COVID-19 Brasil. **2023**, 120, ○
- 7 Phytochemicals of *Withania somnifera* as a Future Promising Drug against SARS-CoV-2: Pharmacological Role, Molecular Mechanism, Molecular Docking Evaluation, and Efficient Delivery. **2023**, 11, 1000 ○
- 6 Impact of antibiotic resistance on sustainable development goals. **2023**, ○
- 5 Trends in management and outcomes of COVID patients admitted to a Swiss tertiary care hospital. **2023**, 13, ○
- 4 Acute kidney injury in COVID-19 patients receiving remdesivir: a systematic review and meta-analysis of randomized clinical trials. **2023**, 100200 ○
- 3 Autochthonous Peruvian Natural Plants as Potential SARS-CoV-2 Mpro Main Protease Inhibitors. **2023**, 16, 585 ○
- 2 Interactions between carbon nanotubes and external structures of SARS-CoV-2 using molecular docking and molecular dynamics. **2023**, 1286, 135604 ○
- 1 Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies. ○